The future of growth-promoting therapy

Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

Abstract

Growth hormone (GH) has been in use for 50. years in children with short stature. Recent developments suggest that our traditional approaches to growth-promoting therapy will be challenged in the following areas:. 1)Diagnostic: The diagnosis of GH deficiency has always been problematic, largely due to limitations inherent in GH stimulation tests and related biochemical measures. The development of new tools for diagnosis of genetic etiologies of hormonal deficiencies and insensitivity, as well as the growing availability of such methodologies, will greatly strengthen existing diagnostic strategies.2)Therapeutic: Long-acting GH preparations are already in clinical trials. IGF-I therapy is approved for treatment of IGF deficiency. Novel approaches to select skeletal dysplasias show promise and will potentially expand our therapeutic armamentarium.3)Monitoring: Traditional weight-based dosing of GH will be supplemented by IGF-based and auxology-based strategies, allowing greater individualization of therapy.4)Safety: Growth-promoting therapies will continue to require careful monitoring of safety. Recent consensus workshops have advocated life-time surveillance programs.5)Ethics: Questions will continue to be raised concerning ethical issues related to growth-promoting therapy in children. The availability of new tools for diagnosis and monitoring will address some, but not all, of these issues.

Original languageEnglish (US)
JournalGrowth Hormone and IGF Research
DOIs
StateAccepted/In press - Jun 4 2015

Fingerprint

Growth Hormone
Growth
Ethics
Therapeutics
Consensus Development Conferences
Safety
Insulin-Like Growth Factor I
Clinical Trials
Weights and Measures

Keywords

  • Growth
  • Growth hormone
  • Growth-promoting
  • IGF

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The future of growth-promoting therapy. / Rosenfeld, Ronald (Ron).

In: Growth Hormone and IGF Research, 04.06.2015.

Research output: Contribution to journalArticle

@article{8fd150e8a8fb4af1b3a1c2a989b4f9f2,
title = "The future of growth-promoting therapy",
abstract = "Growth hormone (GH) has been in use for 50. years in children with short stature. Recent developments suggest that our traditional approaches to growth-promoting therapy will be challenged in the following areas:. 1)Diagnostic: The diagnosis of GH deficiency has always been problematic, largely due to limitations inherent in GH stimulation tests and related biochemical measures. The development of new tools for diagnosis of genetic etiologies of hormonal deficiencies and insensitivity, as well as the growing availability of such methodologies, will greatly strengthen existing diagnostic strategies.2)Therapeutic: Long-acting GH preparations are already in clinical trials. IGF-I therapy is approved for treatment of IGF deficiency. Novel approaches to select skeletal dysplasias show promise and will potentially expand our therapeutic armamentarium.3)Monitoring: Traditional weight-based dosing of GH will be supplemented by IGF-based and auxology-based strategies, allowing greater individualization of therapy.4)Safety: Growth-promoting therapies will continue to require careful monitoring of safety. Recent consensus workshops have advocated life-time surveillance programs.5)Ethics: Questions will continue to be raised concerning ethical issues related to growth-promoting therapy in children. The availability of new tools for diagnosis and monitoring will address some, but not all, of these issues.",
keywords = "Growth, Growth hormone, Growth-promoting, IGF",
author = "Rosenfeld, {Ronald (Ron)}",
year = "2015",
month = "6",
day = "4",
doi = "10.1016/j.ghir.2015.11.003",
language = "English (US)",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1096-6374",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The future of growth-promoting therapy

AU - Rosenfeld, Ronald (Ron)

PY - 2015/6/4

Y1 - 2015/6/4

N2 - Growth hormone (GH) has been in use for 50. years in children with short stature. Recent developments suggest that our traditional approaches to growth-promoting therapy will be challenged in the following areas:. 1)Diagnostic: The diagnosis of GH deficiency has always been problematic, largely due to limitations inherent in GH stimulation tests and related biochemical measures. The development of new tools for diagnosis of genetic etiologies of hormonal deficiencies and insensitivity, as well as the growing availability of such methodologies, will greatly strengthen existing diagnostic strategies.2)Therapeutic: Long-acting GH preparations are already in clinical trials. IGF-I therapy is approved for treatment of IGF deficiency. Novel approaches to select skeletal dysplasias show promise and will potentially expand our therapeutic armamentarium.3)Monitoring: Traditional weight-based dosing of GH will be supplemented by IGF-based and auxology-based strategies, allowing greater individualization of therapy.4)Safety: Growth-promoting therapies will continue to require careful monitoring of safety. Recent consensus workshops have advocated life-time surveillance programs.5)Ethics: Questions will continue to be raised concerning ethical issues related to growth-promoting therapy in children. The availability of new tools for diagnosis and monitoring will address some, but not all, of these issues.

AB - Growth hormone (GH) has been in use for 50. years in children with short stature. Recent developments suggest that our traditional approaches to growth-promoting therapy will be challenged in the following areas:. 1)Diagnostic: The diagnosis of GH deficiency has always been problematic, largely due to limitations inherent in GH stimulation tests and related biochemical measures. The development of new tools for diagnosis of genetic etiologies of hormonal deficiencies and insensitivity, as well as the growing availability of such methodologies, will greatly strengthen existing diagnostic strategies.2)Therapeutic: Long-acting GH preparations are already in clinical trials. IGF-I therapy is approved for treatment of IGF deficiency. Novel approaches to select skeletal dysplasias show promise and will potentially expand our therapeutic armamentarium.3)Monitoring: Traditional weight-based dosing of GH will be supplemented by IGF-based and auxology-based strategies, allowing greater individualization of therapy.4)Safety: Growth-promoting therapies will continue to require careful monitoring of safety. Recent consensus workshops have advocated life-time surveillance programs.5)Ethics: Questions will continue to be raised concerning ethical issues related to growth-promoting therapy in children. The availability of new tools for diagnosis and monitoring will address some, but not all, of these issues.

KW - Growth

KW - Growth hormone

KW - Growth-promoting

KW - IGF

UR - http://www.scopus.com/inward/record.url?scp=84949658903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949658903&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2015.11.003

DO - 10.1016/j.ghir.2015.11.003

M3 - Article

C2 - 26654694

AN - SCOPUS:84949658903

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1096-6374

ER -